4.6 Article

Glucose variability and low bone turnover in people with type 2 diabetes

Journal

BONE
Volume 153, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2021.116159

Keywords

Diabetes; Bone turnover; Sclerostin; Glycemic variability

Funding

  1. Steno Collaborative grant
  2. Novo Nordisk Foundation Denmark [NNF18OC0052064]
  3. Augustinusfonden [15-0542]
  4. Novo Nordic Foundation
  5. A.P. Moller Foundation for the Advancement of Medical Science
  6. Beckett Foundation
  7. Aase and Ejnar Danielsen Foundation
  8. Health Research Fund of Central Denmark Region
  9. Novo Nordisk Fonden [NNF17SA0031230, NNF13OC0003820] Funding Source: researchfish

Ask authors/readers for more resources

In this study, individuals with T2D showed lower levels of bone turnover markers compared to controls, with s-CTX and s-P1NP being negatively associated with glycemic variability. Specifically, s-CTX was negatively associated with both MAGE and dawn glucose levels, while s-P1NP was only negatively associated with dawn glucose levels. Further research is needed to explore the impact of reducing glycemic variability on bone turnover markers.
Introduction: Type 2 diabetes (T2D) is related to an increased fracture risk and low bone turnover. However, the mechanisms are not elucidated. In the present study we investigate the association between glycemic variability and bone turnover markers. Methods: 100 participants with T2D and 100 age and gender matched controls were included in this crosssectional study. All participants with T2D were equipped with a continuous glucose monitoring (CGM) sensor for 3 days (CGMS iPro Continuous Glucose Recorder; Medtronic MiniMed). The dawn glucose levels were defined as a morning period starting 1 h before breakfast ending 1 h post ingestion. On all participants serum (s)-Cterminal cross-linked telopeptide of type-I collagen (CTX), s-procollagen type 1 amino terminal propeptide (P1NP), and s-sclerostin were measured. Results: Participants with T2D displayed significantly lower levels of the bone resorption marker s-CTX and the bone formation marker s-P1NP compared to controls. S-CTX was significantly negatively associated with the mean amplitude of glycemic excursions (MAGE) and the dawn glucose levels whereas s-P1NP only was significantly negatively associated with the dawn glucose levels while it was borderline significantly associated with MAGE (p = 0.05). S-CTX and s-P1NP were significantly lower among the 50% with the highest dawn glucose levels compared to the 50% lowest dawn glucose levels also after adjustment for age, gender, glycated hemoglobin A1c (HbA1c), and body mass index (BMI). Conclusion: We observed that the amplitude of glycemic excursions and rise in dawn glucose was negatively associated with bone turnover markers. Future research is needed to determine whether reduction of the amplitude of glycemic excursions increase bone turnover markers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available